Company also announces addition of serial
entrepreneur Brian Conyer to the team to lead commercialization of
Allurion’s digital assets
Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to
ending obesity, today announced an expanded commercial agreement
with Weight Doctors®—Germany’s leading group of private clinics and
centers for weight loss—and the hiring of Brian Conyer to lead
commercialization of Allurion’s rapidly growing digital assets.
After a successful 2023 in which it managed over 2,000 patients
on Allurion’s Virtual Care Suite (VCS) digital platform, Weight
Doctors has signed with Allurion to expand usage of VCS across new
patients and locations in 2024, including the Netherlands and the
UK. The end patients include not only those treated with the
Allurion Balloon, but also those receiving bariatric surgery and
taking GLP-1 anti-obesity medications. The expanded agreement
illustrates the momentum Allurion is seeing with its Virtual Care
Suite and is an example of the growing pipeline of
commercialization opportunities for Allurion’s digital platform
since launching Coach Iris—Allurion’s 24/7 AI-powered weight loss
coach—in October 2023.
“As interest in weight loss has grown globally, the need for
scalable digital solutions to manage patients and streamline
workflow for providers has grown exponentially,” said Shantanu
Gaur, Founder and CEO of Allurion. “We believe digital solutions
will benefit significantly from the rapidly expanding market
opportunity in weight loss, and we aim to leverage our decade of
expertise to be at the forefront with customers. Our growth with
Weight Doctors underscores the power that Allurion’s digital
platform and suite of AI tools have in fulfilling this need for
clinics serving large volumes of patients.”
The Allurion Virtual Care Suite is a comprehensive set of tools
that can power any weight loss practice: in an Allurion study, 87%
of providers who use the VCS report increased patient
accountability, 88% report increased efficiencies in their
practice, and 82% report increased patient engagement. With the
launch of Coach Iris, the VCS can now provide 24/7 coaching and
guidance to patients across multiple modalities of care, including
weight loss drugs, devices, and bariatric surgery.
“Allurion’s Virtual Care Suite has been transformational for our
business,” said Alexander P. Glaeser, CEO & Managing Partner of
Weight Doctors Group. “Since the global launch of Coach Iris in
October 2023, the software has enabled us to meet and exceed our
patients' needs in a more timely manner. The positive reception of
Coach Iris within our innovative and minimally-invasive weight loss
procedures reflects Weight Doctors Group's commitment to enhancing
patient experiences and continuously working towards optimizing
patient outcomes."
With what it believes is a sizable opportunity ahead, Allurion
has strengthened its team with the addition of Brian Conyer to lead
commercialization of Allurion’s digital assets. Mr. Conyer is a
seasoned entrepreneur with extensive experience in healthcare B2B
and B2C SaaS sales, most recently serving as Co-Founder and CEO of
GIBLIB, a digital medical education platform that counted leading
academic medical centers including Mayo Clinic, Stanford Children’s
Hospital, and UCSF as customers.
“I am thrilled to be joining Allurion at such a pivotal moment,”
said Mr. Conyer. “The demand for weight loss solutions has never
been higher, and I believe Allurion’s VCS digital platform will
become an essential part of any successful weight loss practice
that wants to operate at scale.”
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight-loss platform that combines the Allurion Gastric Balloon,
the world’s first and only swallowable, procedure-less gastric
balloon for weight loss, the Allurion Virtual Care Suite, including
the Allurion Mobile App for consumers, Allurion Insights for
healthcare providers featuring the Iris AI Platform, and the
Allurion Connected Scale. The Allurion Virtual Care Suite is also
available to providers separately from the Allurion Program to help
customize, monitor, and manage weight-loss therapy for patients
regardless of their treatment plan, whether it is gastric balloon,
surgical, medical or nutritional. The Allurion Gastric Balloon is
an investigational device in the United States.
For more information about Allurion and the Allurion Virtual
Care Suite, please visit www.allurion.com.
About Weight Doctors®
The pioneering Weight Doctors® are a leading group of private
clinics and centers for minimally invasive treatments to fight
obesity and overweight. As an international specialist, Weight
Doctors® offer the entire portfolio of treatment options in modern
medicine for effective, medically supervised weight loss at
currently 18 locations in Germany, Austria, the Netherlands, the
UK, South Africa and Namibia: From Weight Doctors® GLP-1
weight-loss injection therapy, to gastric balloon placement, to
minimally invasive gastric surgery as part of the Weight Doctors
BARIATRICS® programme: with Weight Doctors®, patients always find a
promising approach to long-term weight loss based on their weight
loss goal, individual behaviour, lifestyle and medical conditions.
The highlight of the Weight Doctors®, however, is the Weight
Doctors SLEEVE®: The revolutionary treatment concept, exclusively
available at the Weight Doctors®, is the gentlest and most
effective option for permanent stomach reduction without surgery,
with the help of which the stomach volume is reduced by up to 75%
and our patients can lose up to 40kg in body weight.
Forward-Looking Statements
This press release may contain certain forward-looking
statements within the meaning of the U.S. federal and state
securities laws. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions and
include statements regarding Allurion’s expectations for, and
market acceptance of, the Allurion Program. Forward-looking
statements are predictions, projections and other statements about
future events that reflect the current beliefs and assumptions of
Allurion’s management based on information currently available to
them and, as a result, are subject to risks and uncertainties. Many
factors could cause actual future results or developments to differ
materially from the forward-looking statements in this
communication, including but not limited to (i) the ability of
Allurion to obtain regulatory approval for and successfully
commercialize the Allurion Program, (ii) the results of clinical
data from its studies, (iii) the evolution of the markets in which
Allurion competes, (iv) the ability of Allurion to defend its
intellectual property and satisfy regulatory requirements, (v) the
impact of the COVID-19 pandemic on Allurion’s business, (vi)
Allurion’s expectations regarding its market opportunities and
(vii) the risk of economic downturns and a changing regulatory
landscape in the highly competitive industry in which Allurion
operates. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the “Risk Factors” section of the
proxy statement/prospectus contained in Allurion’s Registration
Statement on Form S-4 (333-271862), the company’s Form 8-K filed on
August 7, 2023 (as amended), the company’s and other documents
filed by Allurion from time to time with the U.S. Securities and
Exchange Commission. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Allurion assumes
no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Allurion does not give any assurance
that it will achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240102198325/en/
US Media Brian Ruby ICR (203) 682-8268
brian.ruby@icrinc.com
Global Media Cedric Damour PR Manager +33 7 84 21 02 20
cdamour@allurion.com
Investor Contact Mike Cavanaugh, Investor Relations ICR
Westwicke (617) 877-9641 mike.cavanaugh@westwicke.com
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Dec 2023 to Dec 2024
